Last reviewed · How we verify
Transderm Scop®
Scopolamine blocks muscarinic acetylcholine receptors to prevent nausea and vomiting by reducing vestibular and chemoreceptor trigger zone activity.
Scopolamine blocks muscarinic acetylcholine receptors to prevent nausea and vomiting by reducing vestibular and chemoreceptor trigger zone activity. Used for Prevention of motion sickness, Prevention of postoperative nausea and vomiting (PONV).
At a glance
| Generic name | Transderm Scop® |
|---|---|
| Sponsor | University of Iowa |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptor (non-selective antagonist) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Scopolamine is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors in the central nervous system, particularly in the vomiting center and vestibular nuclei. The transdermal patch formulation provides sustained delivery of the drug, making it effective for motion sickness and postoperative nausea and vomiting (PONV) prevention. Its anticholinergic properties also produce mild sedation, which may contribute to its antiemetic effect.
Approved indications
- Prevention of motion sickness
- Prevention of postoperative nausea and vomiting (PONV)
Common side effects
- Dry mouth
- Drowsiness
- Blurred vision
- Dizziness
- Mydriasis (dilated pupils)
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy (PHASE3)
- Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea (PHASE3)
- Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma (PHASE2)
- Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response (PHASE4)
- Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transderm Scop® CI brief — competitive landscape report
- Transderm Scop® updates RSS · CI watch RSS
- University of Iowa portfolio CI